New Drugs Antiplatelets-Antithrombotics - John Fanikos, RPh, MBA ...

More documents

Recommendations

Info

Heparin RecallJan 17 th , 2008Feb 22 th ,2008Feb 24 th , 2008605040Heparin AftermathHeparin Reported Deaths n=398Deaths3020100Jan-07 May-07 Sep-07 Jan-08 May-08http://energycommerce.Chondroitin Dermatan Heparinhouse.gov20%17.3%Top 5 Medications causing EmergencyDepartment VisitsTargetParenteral agentOral agent15%13.0%Factor IIa (Thrombin)DesirudinXimelagatran10%80706050403020105%0%05.7%4.7%Budnitz DS et al. Ann Intern Med 2007:147:755-65http://www.stoptheclot.org/<strong>New</strong>s/article106.htm3.2%Warfarin Insulin ASA Clopidogrel Digoxin73%Emergency Room Events in WarfarinTreated Patients over 65 Years17%9%Bleed Elevated Lab OtherSkin GI Nose GU ICH Hemoptysis OtherFactor XaFactor VIIa/TF pathwayFactor IXaProtein C PathwayFactor Xa/Factor IIaBivalirudinArgatrobanIdraparinuxM118SSR126517DX-9056aOtamixibanTifacogin (TFPI)Factor VIIaiFactor IXa AptamerProtein CART123 (thrombomodulin)Hexadecasaccharide(SR123781A)Bemiparin (ultra LMWH)Hirsh J et al. Circulation 2007;116:552-660DabigatranOdiparcilRivaroxabanApixabanLY517717YM150Du-176b……TTP889…………
Targeting Blood Clotting Factors: IIa vs XaProcoagulant•Fibrin Formation•Platelet Activation•Feedback activation•TAFI ActivationInflammation•P-Selectinexpression•Cell adhesion•ChemotaxisThrombinAnticoagulant•Protein C, SActivation•ProstacyclinformationCell Proliferation•Tissue Repair•Growth Factorsecretion•AngiogenesisFactor XCell Proliferation &Inflammation•Cytokine release•Smooth muscle cellproliferationProcoagulant•Thrombin Formation•PAI-1 Release<strong>New</strong> Oral Anticoagulants vs WarfarinDrugDabigatranRivaroxabanApixibanWarfarinTargetFactor IIa(Thrombin)Factor XaFactor XaVitamin KepoxidereductaseDosingFixed,Once orTwicedailyFixed,Oncedaily, orTwiceDailyFixed,TwicedailyVariable,OncedailyCoagulationMonitoringNoNoNoYesHalfLife(h)14-179.09-14Eikelboom JW et al. Circulation 2007;116:131-13340RenalClearance(%)10065250InteractionsProton PumpInhibitorsPotentCYP3A4inhibitorsPotentCYP3A4inhibitorsMultipledrugs,dietaryVitamin KDabigatran Etexilate: An Oral DirectThrombin Inhibitor• Specific, competitive, reversible univalentthrombin inhibitor• Inhibits free and fibrin-bound thrombinactivity• Pro-Drug rapidly converted to active form• Rapid onset within 2 hours• Low bioavailability, 3.5-5%• Half life 12-17 hours• Renal clearance as glucuronic acidconjugate• Cytochrome P450 system isoenzymes arenot involved with metabolism, noinduction or inhibition.• Prolongs aPTT in a non-linear fashion• Approved in Europe and Canada Baetz BE. Pharmacotherapy 2008.Perzborn E. J Thromb Haemost 2005.Kubitza D., J Clin Pharmacol 2007.Rendix,Pradaxa ®Eikelboom JE. Thromb Haemostasis 2009.RE-COVER Trial DesignObjectiveconfirmationof VTE72 hE RE= enrollmentR= randomizationSingledummyperiodWarfarinplaceboWarfarinInitial parenteraltherapyUntil INR ≥2.0 attwo consecutivemeasurements(8-11 days)Double-dummy periodDabigatran etexilate 150 mg bidWarfarin placeboDabigatran etexilate placebo bidWarfarin(INR 2.0–3.0)6 monthsEnd of treatment30 daysfollow upSchulman S et al. N Engl J Med2009:361:2342-52Cumulative Risk of Recurrent VenousThromboembolism and Related DeathCumulative Risk of First Event of MajorBleeding and of Any BleedingEstimated Cumulative Risk (%)Estimated Cumulative Risk (%)DabigatranWarfarin, any bleedingDabigatran, any bleedingWarfarin, MBEDabigatran, MBEWarfarin and any bleedingWarfarinDabigatran andany bleedingNo. at riskMonths Since RandomizationDabigatran andmajor bleedingWarfarin andmajor bleedingDabigatran was non-inferior to warfarin for prevention of recurrent or fatal VTE(P
Page 1: Novel Anticoagulants andAntiplatele
Page 5 and 6: Common Adverse EventsAdverse events
Page 7 and 8: Apixaban: An Oral Direct Factor Xa
Page 9 and 10: BOREALIS-AFBiotinylated Idraparinux
Page 11 and 12: Total major bleedingK-M estimated r

New Drugs Antiplatelets-Antithrombotics - John Fanikos, RPh, MBA ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?